Elanco Animal Health Incorporated logo ELAN - Elanco Animal Health Incorporated

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 15
HOLD 4
SELL 2
STRONG
SELL 0
| PRICE TARGET: $28.00 DETAILS
HIGH: $30.00
LOW: $26.00
MEDIAN: $28.00
CONSENSUS: $28.00
UPSIDE: 14.24%

Stock News

Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility

Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility

The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipeline INDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with mAb solutions on the market today, the expansion further strengthens Elanco's leadership in the biologics space.

Aug 26, 2026 04:30 AM • prnewswire.com
Elanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform

Elanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform

Elanco Animal Health is transitioning from a leveraged consolidator to an innovative competitor, with new products driving EBITDA growth and market share gains. ELAN's innovation portfolio, including Zenrelia, Credelio Quattro, and Befrena, is capturing share in dermatology and parasiticide markets, challenging Zoetis' key franchises. Margin expansion and deleveraging are underway, supported by the Ascend program and strong cash flow; net leverage is targeted below 3.0x by 2027.

Aug 12, 2026 01:02 AM • seekingalpha.com
Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra provides livestock producers with a vital tool in the prevention of New World screwworm infestations. Elanco also offers producers Negasunt® Powder (coumaphos, propoxur, and sulfanilamide topical powder) and Tanidil®, which received emergency authorizations earlier this year, as well as EPA-registered Catron™ IV.

Aug 07, 2026 10:20 AM • prnewswire.com
Elanco Animal Health Reports Second Quarter 2026 Results

Elanco Animal Health Reports Second Quarter 2026 Results

Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2026 Financial Results: Revenue of $1,368 million, an increase of 10% year-over-year; 8% organic constant currency growth Reported Net Income of $54 million, Adjusted Net Income of $174 million Adjusted EBITDA of $288 million; Adjusted EBITDA Margin of 21.2% Reported EPS of $0.11, Adjusted EPS of $0.34 Net leverage ratio of 3.1x Adjusted EBITDA Full Year 2026 Guidance: Raising innovation revenue target to $1.25 billion Raising revenue guidance to $5.09 billion to $5.14 billion, or 6% to 7% organic constant currency growth Raising Adjusted EBITDA to $1.01 billion to $1.035 billion, a year-over-year increase of 13% at midpoint Raising Adjusted EPS to $1.10 to $1.16, a year-over-year increase of 20% at midpoint Improving year-end net leverage ratio target to approximately 3.0x Adjusted EBITDA INDIANAPOLIS, Aug. 5, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the second quarter of 2026, provided guidance for the third quarter of 2026, and updated guidance for the full year 2026. "Elanco's second quarter results demonstrate our momentum and leadership in the attractive animal health industry," stated Jeff Simmons, President and CEO of Elanco.

Aug 05, 2026 02:27 AM • prnewswire.com
Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs

Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs

Report highlights Elanco's impact through innovation, expanded access to animal care, a stronger and more sustainable food system and investment in people and communities INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today released its 2025 Impact Report, "Leading with Purpose," highlighting how the company brings together purpose, innovation and business strategy to help address some of society's most pressing challenges. The report details Elanco's progress across four interconnected areas: going beyond for animals, customers, society and its people.

Jul 31, 2026 03:32 AM • prnewswire.com

Price Targets